ScholarIQanswers from OpenAlex
Renown Health
InstitutionResearch output, impact & collaborations
Renown Health is a institution indexed in ScholarIQ from OpenAlex.
What is known about Renown Health?
ScholarIQrecord summary
Renown Health is a research organisation in Reno, United States. OpenAlex records 487 works and 14,666 citations for it. 1 researchers list it as their most recent affiliation.
How many works does Renown Health have?
ScholarIQindexed works
Renown Health has 487 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Renown Health have?
ScholarIQcitation count
Renown Health has 14,666 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Renown Health?
ScholarIQresearcher count
Renown Health has 1 researchers in the ScholarIQ index.
What is the average h-index at Renown Health?
ScholarIQavg h-index
Renown Health has an average h-index of 63 in OpenAlex.
What is the ROR of Renown Health?
ScholarIQror
The ROR for Renown Health is on the source record.
What is the OpenAlex record for Renown Health?
ScholarIQopenalex
The OpenAlex for Renown Health is on the source record.
Who are the most-cited researchers behind Renown Health?
ScholarIQtop researchers by citations
What are the most-cited papers on Renown Health?
ScholarIQmost cited works
2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline
Thomas J. Smith, James Khatcheressian, Gary H. Lyman, Howard Ozer, Jamés O. Armitage, Lodovico Balducci, Charles L. Bennett, Scott B. Cantor, Jeffrey Crawford, Scott J. Cross, George D. Demetri, Christopher E. Desch, Philip A. Pizzo, Charles A. Schiffer, Lee S. Schwartzberg, Mark R. Somerfield, George Somlo, James C. Wade, James L. Wade, Rodger J. Winn, Antoinette J. Wozniak, Antonio C. Wolff
A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy
Matti Aapro, H. S. Rugo, Antônio Rossi, Giada Rizzi, Maria Elisa Borroni, Igor Bondarenko, Tomasz Sarosiek, Cristina Oprean, Servando Cardona‐Huerta, Vito Lorusso, M. Karthaus, Lee S. Schwartzberg, Steven M. Grunberg
Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)
David R. Spigel, Michael McCleod, Robert M. Jotte, Lawrence H. Einhorn, Leora Horn, David Waterhouse, Ben Creelan, Sunil Babu, Natasha B. Leighl, Jason C. Chandler, Félix Couture, George P. Keogh, Glenwood Goss, Davey B. Daniel, Edward B. Garon, Lee S. Schwartzberg, Rohini Sen, Beata Korytowsky, Ang Li, Nivedita Aanur, Maen Hussein
How much of the research on Renown Health is open access?
ScholarIQopen access share
67%OPEN ACCESS